Eagle Strategies’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$326K Buy
13,556
+202
+2% +$5.28K 0.03% 226
2026
Q1
$375K Buy
13,354
+167
+1% +$4.45K 0.04% 202
2025
Q4
$328K Sell
13,187
-204
-2% -$5.14K 0.04% 210
2025
Q3
$341K Sell
13,391
-49
-0.4% -$1.21K 0.05% 196
2025
Q2
$326K Buy
13,440
+161
+1% +$3.75K 0.05% 182
2025
Q1
$337K Buy
13,279
+1,067
+9% +$27.9K 0.06% 166
2024
Q4
$324K Buy
12,212
+2,852
+30% +$77.4K 0.06% 169
2024
Q3
$271K Sell
9,360
-4,003
-30% -$117K 0.05% 177
2024
Q2
$374K Buy
13,363
+2,739
+26% +$75.4K 0.07% 151
2024
Q1
$295K Buy
10,624
+170
+2% +$4.72K 0.07% 218
2023
Q4
$301K Sell
10,454
-205
-2% -$6.2K 0.06% 158
2023
Q3
$354K Sell
10,659
-950
-8% -$33.6K 0.09% 134
2023
Q2
$426K Buy
11,609
+1,274
+12% +$49.6K 0.1% 128
2023
Q1
$422K Buy
10,335
+468
+5% +$20.2K 0.11% 122
2022
Q4
$506K Sell
9,867
-11
-0.1% -$527 0.15% 102
2022
Q3
$432K Buy
9,878
+599
+6% +$29.1K 0.23% 71
2022
Q2
$487K Sell
9,279
-1,122
-11% -$57.2K 0.18% 93
2022
Q1
$538K Buy
10,401
+1,256
+14% +$65.2K 0.21% 81
2021
Q4
$540K Buy
+9,145
New +$453K 0.21% 84

Other funds holding PFE

Eagle Strategies's PFE Position: Q2 2026 in Review

Eagle Strategies increased its Pfizer (PFE) stake by 1.5% in Q2 2026, buying an estimated $5.28K and bringing the position to 13,556 shares worth $326K. The position accounts for 0.03% of the portfolio, ranked #226.

Eagle Strategies first reported a position in PFE in Q4 2021 and has held it in 19 quarters since. The position peaked at $540K in Q4 2021. 1,421 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Eagle Strategies held 13,556 shares of Pfizer worth $326K as of Q2 2026.
  • Eagle Strategies bought 202 Pfizer shares in Q2 2026, an estimated $5.28K.
  • Pfizer made up 0.03% of Eagle Strategies's portfolio in Q2 2026, its #226 holding.
  • Eagle Strategies first reported a position in Pfizer in Q4 2021 and has held it in 19 quarters since.
  • Eagle Strategies's Pfizer position peaked at $540K in Q4 2021.
  • 1,421 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Eagle Strategies's 13F filing for Q2 2026, filed 21 Jul 2026.